Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 3.5 EUR -1.63% Market Closed
Market Cap: 165.9m EUR
Have any thoughts about
Nanobiotix SA?
Write Note

Nanobiotix SA
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nanobiotix SA
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Nanobiotix SA
PAR:NANO
Cash & Cash Equivalents
€75.3m
CAGR 3-Years
-10%
CAGR 5-Years
19%
CAGR 10-Years
11%
Valneva SE
PAR:VLA
Cash & Cash Equivalents
€131.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Cash & Cash Equivalents
€61.6m
CAGR 3-Years
-16%
CAGR 5-Years
-26%
CAGR 10-Years
-1%
Inventiva SA
PAR:IVA
Cash & Cash Equivalents
€10.1m
CAGR 3-Years
-52%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Cash & Cash Equivalents
€89m
CAGR 3-Years
7%
CAGR 5-Years
62%
CAGR 10-Years
20%
OSE Immunotherapeutics SA
PAR:OSE
Cash & Cash Equivalents
€25.9m
CAGR 3-Years
-2%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Nanobiotix SA
Glance View

Market Cap
164.9m EUR
Industry
Biotechnology

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

NANO Intrinsic Value
5.23 EUR
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Nanobiotix SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
75.3m EUR

Based on the financial report for Jun 30, 2024, Nanobiotix SA's Cash & Cash Equivalents amounts to 75.3m EUR.

What is Nanobiotix SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
11%

Over the last year, the Cash & Cash Equivalents growth was 248%. The average annual Cash & Cash Equivalents growth rates for Nanobiotix SA have been -10% over the past three years , 19% over the past five years , and 11% over the past ten years .

Back to Top